Lake Street analyst Eric Martinuzzi raised the firm’s price target on OptimizeRx to $17 from $14 and keeps a Buy rating on the shares after the company issued guidance for 2023 and 2024 revenue. The firm is “pleased” to see the company return to better than expected growth and likes how the 2023 Dynamic Audience Activation Platform, or DAAP, deals de-risk 2024 execution, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OPRX:
- OptimizeRx sees 2024 revenue at least $110M, consensus $110.29M
- OptimizeRx sees 2023 revenue exceeding $68M-$70M, consensus $68.78M
- OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update
- OptimizeRx initiated with an Equal Weight at Barclays
- OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
